Do the benefits of currently available treatments justify early diagnosis and treatment of amyotrophic lateral sclerosis? Arguments against

Neurology

Volumn 53, Issue 8 SUPPL., 1999, Pages

  Ludolph, A C ^a   Riepe, M W ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ASTHENIA; EARLY DIAGNOSIS; GASTROINTESTINAL SYMPTOM; HUMAN; NEUROPROTECTION; PRIORITY JOURNAL;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; HUMANS; NEUROPROTECTIVE AGENTS; RILUZOLE;

EID: 0032734523     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Charcot JM. Leçons sur les maladies du systéme nerveux faites à la Salpetrière. Prog Med (Paris) 1874:213-242.
2. Bensimon G, Lacomblez L, Meininger V, and the ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
3. Friedländer RM, Brown RH, Gagliardini V, Wang J, Yuan J. Inhibition of ICE slows ALS in mice. Science 1997;388:31.
4. Gurney M, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147-157.
5. Kostic V, Jackson-Lewis V, de Bilbao F, Dubois-Dauphin M, Przedborski S. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 1997; 277:559-562.
6. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-1431.
7. Louvel E, Hugon J, Doble A. Therapeutic advances in amyotrophic lateral sclerosis. Trends Pharm Sci 1997;18:196-203.
8. Miller RG, Moore D, Young LA, et al., and the WALS Study Group. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 1996;47:1383-1388.
9. Lai EC, Felice KJ, Festoff BW, et al., and the North America ALS/IGF-I Study Group. Effect of recombinant human insulin-like growth factor-I on progression of ALS. Neurology 1997;49:1621-1630.
10. ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996;46:1244-1249.
11. Miller RG, Petajan JH, Bryan WW, et al., and the rhCNTF ALS Study Group. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. Ann Neurol 1996;39:256-260.
12. Data on file, Rhône-Poulenc Rorer.
13. Riviére M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 1998;55:526-528.
14. Kasischke K, Ludolph AC, Riepe MW. NMDA-antagonists reverse increased hypoxic tolerance by preceding chemical hypoxia. Neurosci Lett 1996;214:1-4.
15. Ludolph AC, Knirsch U. Problems and pitfalls in the diagnosis of ALS. J Neurol Sci 1999;165(suppl 1):14-20.